New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
The authors propose a promising new therapy for the treatment of Raynaud's phenomenon, with parenteral prostacyclin (carbaprostacyclin) and a serotonergic S2-receptor antagonist (ketanserin) given orally. They studied 31 patients, 22 treated with ketanserin and carbaprostacyclin, 9 with carbaprostacyclin alone. Both groups demonstrated successful results and a significant improvement in measurements performed by photoplethysmography and transcutaneous pulse oximetry.
Pola
P
P
Department of Angiology, Catholic University of Sacred Heart, Rome, Italy.
Tondi
P
P
Serricchio
M
M
Favuzzi
A
A
Gerardino
L
L
D000328:Adult; D000368:Aged; D001785:Blood Gas Monitoring, Transcutaneous; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007650:Ketanserin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017156:Photoplethysmography; D011465:Prostaglandins, Synthetic / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D011465:Prostaglandins, Synthetic; C026678:carboprostacyclin; D007650:Ketanserin; D011464:Epoprostenol